Scholarlink

Purpose <p>To compare the clinical efficacy and safety of weight-based versus body surface area–based single-dose methotrexate (MTX) protocols in the medical management of tubal ectopic pregnancy.</p> Methods <p>In this retrospective cohort study, 84 hemodynamically stable patients with tubal ectopic pregnancy treated with systemic MTX between 2020 and 2024 were analyzed. Patients received MTX either at 1&#xa0;mg/kg or 50&#xa0;mg/m<sup>2</sup> intramuscularly. Demographic, biochemical and clinical characteristics, early beta-human chorionic gonadotropin (β-hCG) kinetics, need for repeat MTX dosing and surgical intervention, and adverse events were compared between the two dosing strategies.</p> Results <p>Of 84 patients, 56 were treated with the body surface area–based protocol and 28 with the weight-based protocol. Baseline characteristics and initial β-hCG levels were comparable. The need for an additional MTX dose was significantly lower in the body surface area group than in the weight-based group (12.5% vs 32.1%; <i>p</i> = 0.031). Surgical intervention was required in 13 patients (15.4%) without a significant difference between groups (<i>p</i> = 0.135). No MTX-related adverse events were observed.</p> Conclusion <p>Body surface area–based MTX dosing was associated with a significantly lower need for repeat dosing without increasing the rate of surgical conversion or adverse events. Prospective, adequately powered studies are warranted to optimize MTX dosing strategies in tubal ectopic pregnancy and confirm long-term efficacy and safety.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Body Surface Area versus Weight-Based Methotrexate Dosing in Tubal Ectopic Pregnancy: A Retrospective Cohort Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月26日

查看全文
  • Murat Cagan,
  • Mert Eyupoglu,
  • Ezgi Aydin,
  • Edip Alptug Kir,
  • Burcu Gedik,
  • Erdem Fadiloglu,
  • Ozgur Deren

摘要

Purpose

To compare the clinical efficacy and safety of weight-based versus body surface area–based single-dose methotrexate (MTX) protocols in the medical management of tubal ectopic pregnancy.

Methods

In this retrospective cohort study, 84 hemodynamically stable patients with tubal ectopic pregnancy treated with systemic MTX between 2020 and 2024 were analyzed. Patients received MTX either at 1 mg/kg or 50 mg/m2 intramuscularly. Demographic, biochemical and clinical characteristics, early beta-human chorionic gonadotropin (β-hCG) kinetics, need for repeat MTX dosing and surgical intervention, and adverse events were compared between the two dosing strategies.

Results

Of 84 patients, 56 were treated with the body surface area–based protocol and 28 with the weight-based protocol. Baseline characteristics and initial β-hCG levels were comparable. The need for an additional MTX dose was significantly lower in the body surface area group than in the weight-based group (12.5% vs 32.1%; p = 0.031). Surgical intervention was required in 13 patients (15.4%) without a significant difference between groups (p = 0.135). No MTX-related adverse events were observed.

Conclusion

Body surface area–based MTX dosing was associated with a significantly lower need for repeat dosing without increasing the rate of surgical conversion or adverse events. Prospective, adequately powered studies are warranted to optimize MTX dosing strategies in tubal ectopic pregnancy and confirm long-term efficacy and safety.